Published Paper Details:

Monoclonal antibodies (mAbs) are among the most important therapeutic protein types used to treat a variety of diseases (e.g., oncology, inflammation and autoimmune diseases). One major obstacle to the creation of novel antibodies is the identification of new pharmacological targets, yet monoclonal antibody technologies are still evolving to provide drugs with steadily better safety profiles. There are various prospects for producing subcutaneous formulations of antibodies, for example, to improve patient compliance, reduce costs, and control the lifespan of the drug. Nevertheless, Medication based on monoclonal antibodies has a few limitations that limit its therapeutic use. The major concerns are their short pharmacokinetic characteristics and stability problems during manufacture, transit, and storage that might result in protein aggregation and denaturation. Monoclonal antibodies (mAb) can be coupled to novel surface-functionalized cross-linked nanogels to achieve targeted drug delivery. In biomedical research, disease detection, and cancer and other types of disease treatment, monoclonal antibodies (mAb) are essential tools. A monoclonal antibody is an example of a mediator that can target nanoparticles with precision. Immune cells that produce only one kind of antibody, called monoclonal antibodies, are all clones of a single parent cell. It has a property obtained from myeloma cells, which allows it to continuously divide at the same time. A lung cancer nanoparticle targeted delivery method using a monoclonal antibody as a targeting mediator. Hybridoma technique refers to the production of monoclonal antibodies in artificial media using hybridomas that are selective for spleen and myeloma cells. They develop a hybrid cell that is capable of making several monoclonal antibodies against an antigen. Hybridoma technology is the method used to manufacture monoclonal antibodies. Due to the enormous no. of foreign substance present on the cancer cell surface , mAb are broadly used to transport nanoparticles which helps to improve therapeutic aiming to the cancerous cells.